About Us
Research Watch
नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकटFrontline Perspectives on Nursing Leadership in NepalProtecting the Smallest Lungs from the Hidden Grip of RSV in KathmanduThe Heavy Burden of Bullying on Student Wellbeing in NepalThe Emerging Landscape of Thyroid Health in Central NepalHow a Recent Western Nepal Study is Redefining Anemia DiagnosisHow H. Pylori is Impacting the Health of Karnali’s High-Altitude CommunitiesSweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s YouthHow Missing Checklists and Protocols are Costing Lives in Nepal’s ERsWhy Your Lungs May Hold the Secret to Your Stress Levelsनेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकटFrontline Perspectives on Nursing Leadership in NepalProtecting the Smallest Lungs from the Hidden Grip of RSV in KathmanduThe Heavy Burden of Bullying on Student Wellbeing in NepalThe Emerging Landscape of Thyroid Health in Central NepalHow a Recent Western Nepal Study is Redefining Anemia DiagnosisHow H. Pylori is Impacting the Health of Karnali’s High-Altitude CommunitiesSweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s YouthHow Missing Checklists and Protocols are Costing Lives in Nepal’s ERsWhy Your Lungs May Hold the Secret to Your Stress Levels

Time-Updated Hematuria and Kidney Disease Progression in IgAN.

Researchers

Chen Tang, Feng-Lei Si, Pei Chen, Wan-Yin Hou, Hong-Yu Yang, Ji-Cheng Lv, Su-Fang Shi, Xu-Jie Zhou, Li-Jun Liu, Hong Zhang

Abstract

Hematuria is a hallmark feature of IgA nephropathy (IgAN); however, its long-term impact on kidney outcomes remains incompletely characterized because of time-dependent confounding and lack of a standardized cutoff. This study evaluated the longitudinal association between hematuria and kidney disease progression. We included 1771 participants with biopsy-proven IgAN. Hematuria was categorized into the following 4 groups: &lt; 10, 10 to &lt; 20, 20 to &lt; 100, and &#x2265; 100 red blood cells (RBC)/&#x3bc;l. The primary outcome was a composite kidney outcome (40% estimated glomerular filtration rate [eGFR] decline or kidney failure). Conventional Cox proportional hazards models were used to assess baseline hematuria, whereas marginal structural models (MSMs) were employed to evaluate time-updated hematuria, accounting for time-dependent confounders and fluctuations in clinical parameters. During a median follow-up of 48 months, the primary outcome occurred in 487 (27.5%) participants. In the fully adjusted baseline Cox model, baseline hematuria was not significantly associated with the primary outcome. In contrast, MSMs revealed that time-updated hematuria &#x2265; 100 RBC/&#x3bc;l was significantly associated with an increased risk of progression (hazard ratio [HR]: 1.53; 95% confidence interval [CI]: 1.14-2.06). The adverse impact was particularly pronounced in subgroups with a baseline eGFR &lt; 60 ml/min per 1.73 m<sup>2</sup> and those with baseline proteinuria &#x2265; 0.5 g/d. Even moderate time-updated hematuria (20 to &lt; 100 RBC/&#x3bc;l) was correlated with a substantially elevated risk (HR: 1.89; 95% CI: 1.33-2.72) in the subgroup with eGFR &lt;60 ml/min per 1.73 m<sup>2</sup>. Our findings suggest that persistent hematuria &#x2265; 100 RBC/&#x3bc;l may serve as a valuable risk stratification standard, particularly given the significantly magnified risk in patients with pre-existing renal impairment or uncontrolled proteinuria.
Source: PubMed (PMID: 42471814)View Original on PubMed